HIV entry inhibitors: progress in development and application.
- Author:
Wei-hong LAI
1
;
Li HUANG
;
Chin-ho CHEN
Author Information
1. Department of Surgery, Duke University Medical Center, Surgical Oncology Research Facility, Durham, North Carolina 27710, USA.
- Publication Type:Journal Article
- MeSH:
Anti-HIV Agents;
chemistry;
pharmacology;
therapeutic use;
CCR5 Receptor Antagonists;
CD4 Antigens;
drug effects;
Cyclohexanes;
pharmacology;
therapeutic use;
Drug Resistance, Viral;
HIV Envelope Protein gp120;
pharmacology;
HIV Envelope Protein gp41;
pharmacology;
therapeutic use;
HIV Fusion Inhibitors;
chemistry;
pharmacology;
therapeutic use;
HIV Infections;
drug therapy;
HIV-1;
drug effects;
Humans;
Molecular Structure;
Peptide Fragments;
pharmacology;
therapeutic use;
Receptors, CCR5;
physiology;
Receptors, CXCR4;
antagonists & inhibitors;
Receptors, Chemokine;
drug effects;
Triazoles;
pharmacology;
therapeutic use
- From:
Acta Pharmaceutica Sinica
2010;45(2):131-140
- CountryChina
- Language:English
-
Abstract:
This review discusses recent progress in the development of anti-HIV agents, with emphasis on small molecule HIV-1 entry inhibitors. The entry inhibitors primarily target HIV-1 envelope glycoproteins or the cellular receptors, CD4 and chemokine receptors. Two of the entry inhibitors, enfuvirtide and maraviroc, have been approved by the US FDA for AIDS therapy. The drug resistance associated with some of the entry inhibitors will also be discussed.
